Apilimod compositions and methods for using same
Inventors
Lichenstein, Henri • Rothberg, Jonathan M. • Gayle, Sophia • Beeharry, Neil • Beckett, Paul • LANDRETTE, Sean • Conrad, Chris • Dyer, Matt • Xu, Tian
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11266654-B2
Publication Date
2022-03-08
Expiration Date
Abstract
The present invention relates to methods for treating cancer with apilimod and related compositions and methods.
Core Innovation
The invention provides a method for treating cancer using apilimod, or a pharmaceutically acceptable salt thereof. In particular, the method is described for treating follicular lymphoma in a human subject in need thereof by administering apilimod in a therapeutically effective amount. Apilimod compositions include apilimod in free base form or in pharmaceutically acceptable salt forms.
The disclosed treatment rationale is based on cytotoxic and anti-proliferative activity in TSC2-null and mTOR-activated cells. The disclosure further describes anti-proliferative activity across diverse cancer cell lines and especially in B-cell lymphomas, including non-Hodgkin's lymphoma and follicular lymphoma.
The document identifies PIKfyve as a high-affinity binding target of apilimod and describes a mechanism involving apoptosis, autophagy, and disruption of intracellular trafficking. The disclosure also states that sensitivity is not correlated with IL-12/IL-23 or c-Rel expression.
Claims Coverage
The identified independent claim covers one inventive feature directed to a method for treating follicular lymphoma in a human subject by administering apilimod, or a pharmaceutically acceptable salt thereof, in a therapeutically effective amount.
Treating follicular lymphoma with apilimod administration
A method for treating follicular lymphoma in a human subject in need thereof, comprising administering a pharmaceutical composition comprising apilimod, or a pharmaceutically acceptable salt thereof, to the subject in a therapeutically effective amount.
The core inventive coverage is therapeutically effective administration of apilimod, or a pharmaceutically acceptable salt thereof, to treat follicular lymphoma in a human subject in need thereof.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treating follicular lymphoma in a human subject in need thereof using apilimod, or a pharmaceutically acceptable salt thereof, in a therapeutically effective amount.
Treatment in the setting of refractory or recurrent follicular lymphoma.
Interested in licensing this patent?